Varicella Zoster (HHV-3) Infections – Pipeline Review, H2 2012
出 版 商：Global Markets Direct
出版日期：2012/08/31
頁 數：73頁
文件格式：PDF
價 格：
USD 2,000 (Single-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
Varicella Zoster (HHV-3) Infections – Pipeline Review, H2 2012
Summary
Global Markets Direct’s, 'Varicella Zoster (HHV-3) Infections - Pipeline Review, H2 2012', provides an overview of the Varicella Zoster (HHV-3) Infections therapeutic pipeline. This report provides information on the therapeutic development for Varicella Zoster (HHV-3) Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Varicella Zoster (HHV-3) Infections. 'Varicella Zoster (HHV-3) Infections - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- A snapshot of the global therapeutic scenario for Varicella Zoster (HHV-3) Infections.
- A review of the Varicella Zoster (HHV-3) Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Varicella Zoster (HHV-3) Infections pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Varicella Zoster (HHV-3) Infections.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Varicella Zoster (HHV-3) Infections pipeline depth and focus of Varicella Zoster (HHV-3) Infections therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Summary
Global Markets Direct’s, 'Varicella Zoster (HHV-3) Infections - Pipeline Review, H2 2012', provides an overview of the Varicella Zoster (HHV-3) Infections therapeutic pipeline. This report provides information on the therapeutic development for Varicella Zoster (HHV-3) Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Varicella Zoster (HHV-3) Infections. 'Varicella Zoster (HHV-3) Infections - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- A snapshot of the global therapeutic scenario for Varicella Zoster (HHV-3) Infections.
- A review of the Varicella Zoster (HHV-3) Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Varicella Zoster (HHV-3) Infections pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Varicella Zoster (HHV-3) Infections.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Varicella Zoster (HHV-3) Infections pipeline depth and focus of Varicella Zoster (HHV-3) Infections therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Varicella Zoster (HHV-3) Infections Overview 8
Therapeutics Development 9
An Overview of Pipeline Products for Varicella Zoster (HHV-3) Infections 9
Varicella Zoster (HHV-3) Infections Therapeutics under Development by Companies 11
Varicella Zoster (HHV-3) Infections Therapeutics under Investigation by Universities/Institutes 13
Late Stage Products 14
Comparative Analysis 14
Mid Clinical Stage Products 15
Comparative Analysis 15
Early Clinical Stage Products 16
Comparative Analysis 16
Discovery and Pre-Clinical Stage Products 17
Comparative Analysis 17
Varicella Zoster (HHV-3) Infections Therapeutics – Products under Development by Companies 18
Varicella Zoster (HHV-3) Infections Therapeutics – Products under Investigation by Universities/Institutes 19
Companies Involved in Varicella Zoster (HHV-3) Infections Therapeutics Development 20
GlaxoSmithKline plc 20
Merck & Co., Inc. 21
Inhibitex, Inc. 22
Nutra Pharma Corporation 23
Summit Corporation plc 24
Clavis Pharma ASA 25
aRigen Pharmaceuticals, Inc. 26
Sinovac Biotech Ltd. 27
Epiphany Biosciences, Inc. 28
EMS S.A. 29
Varicella Zoster (HHV-3) Infections – Therapeutics Assessment 30
Assessment by Monotherapy Products 30
Assessment by Combination Products 31
Assessment by Route of Administration 32
Assessment by Molecule Type 34
Drug Profiles 36
FV-100 - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
RPI-78M - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
ARYS-01 - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
CP-4018 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
EPB-348 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Zoster - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Varicella-Zoster Vaccine - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
ZOSTAVAX - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
V212 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
Antiviral Program - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
Zostavax - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
Famciclovir - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
GSK208136 - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
Chickenpox Vaccine - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
Varilrix + Priorix-Tetra - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
Zostavax - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
Varicella Zoster (HHV-3) Infections Therapeutics – Drug Profile Updates 59
Varicella Zoster (HHV-3) Infections Therapeutics – Discontinued Products 62
Varicella Zoster (HHV-3) Infections Therapeutics - Dormant Products 63
Varicella Zoster (HHV-3) Infections – Product Development Milestones 65
Featured News & Press Releases 65
Jul 18, 2012: Agenus Annnounces Intiation Of Phase III Clinical Trial Of GSK's Herpes Zoster Vaccine Candidate In Immunocompromised Patients 65
Mar 15, 2012: CHMP Adopts Positive Opinion Recommending Variation To Terms Of Marketing Authorization For Proquad 66
Jan 28, 2011: Depomed Announces FDA Approval Of GRALISE Once-Daily Tablets For Treatment Of Post-Herpetic Neuralgia 66
Dec 13, 2010: Inhibitex Reports Promising Top-Line Results From Phase II Shingles Trial With FV-100 67
Oct 15, 2010: Inhibitex Completes Enrollment In Phase II Clinical Trial Of FV-100 In Shingles Patients 68
Aug 23, 2010: GSK Initiates Phase III Clinical Trials To Develop Herpes Zoster Vaccine For Prevention Of Shingles 69
Jul 22, 2010: Inhibitex Reports Independent Data Safety Monitoring Board Recommends Continuation Of Phase II Clinical Trial Of FV-100 69
Nov 18, 2009: Epiphany Announces Positive Results Of Its Drug Candidate Valomaciclovir From Its Phase 2b Trial In Shingles 69
Sep 09, 2008: Epiphany Biosciences Announces To Continue Phase 2 shingles Study After Interim Analysis 70
Nov 07, 2007: Epiphany Biosciences Reports Initiation And Enrollment In Valomaciclovir Study For Shingles 71
Appendix 72
Methodology 72
Coverage 72
Secondary Research 72
Primary Research 72
Expert Panel Validation 72
Contact Us 73
Disclaimer 73
List of Tables
Number of Products Under Development for Varicella Zoster (HHV-3) Infections, H2 2012 9
Products under Development for Varicella Zoster (HHV-3) Infections – Comparative Analysis, H2 2012 10
Number of Products under Development by Companies, H2 2012 12
Number of Products under Investigation by Universities/Institutes, H2 2012 13
Comparative Analysis by Late Stage Development, H2 2012 14
Comparative Analysis by Mid Clinical Stage Development, H2 2012 15
Comparative Analysis by Early Clinical Stage Development, H2 2012 16
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 17
Products under Development by Companies, H2 2012 18
Products under Investigation by Universities/Institutes, H2 2012 19
GlaxoSmithKline plc, H2 2012 20
Merck & Co., Inc., H2 2012 21
Inhibitex, Inc., H2 2012 22
Nutra Pharma Corporation, H2 2012 23
Summit Corporation plc, H2 2012 24
Clavis Pharma ASA, H2 2012 25
aRigen Pharmaceuticals, Inc., H2 2012 26
Sinovac Biotech Ltd., H2 2012 27
Epiphany Biosciences, Inc., H2 2012 28
EMS S.A., H2 2012 29
Assessment by Monotherapy Products, H2 2012 30
Assessment by Combination Products, H2 2012 31
Assessment by Stage and Route of Administration, H2 2012 33
Assessment by Stage and Molecule Type, H2 2012 35
Varicella Zoster (HHV-3) Infections Therapeutics – Drug Profile Updates 59
Varicella Zoster (HHV-3) Infections Therapeutics – Discontinued Products 62
Varicella Zoster (HHV-3) Infections Therapeutics – Dormant Products 63
Varicella Zoster (HHV-3) Infections Therapeutics – Dormant Products (Contd..1) 64
List of Figures
Number of Products under Development for Varicella Zoster (HHV-3) Infections, H2 2012 9
Products under Development for Varicella Zoster (HHV-3) Infections – Comparative Analysis, H2 2012 10
Products under Development by Companies, H2 2012 11
Products under Investigation by Universities/Institutes, H2 2012 13
Late Stage Products, H2 2012 14
Mid Clinical Stage Products, H2 2012 15
Early Clinical Stage Products, H2 2012 16
Discovery and Pre-Clinical Stage Products, H2 2012 17
Assessment by Monotherapy Products, H2 2012 30
Assessment by Combination Products, H2 2012 31
Assessment by Route of Administration, H2 2012 32
Assessment by Stage and Route of Administration, H2 2012 33
Assessment by Molecule Type, H2 2012 34
Assessment by Stage and Molecule Type, H2 2012 35
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Varicella Zoster (HHV-3) Infections Overview 8
Therapeutics Development 9
An Overview of Pipeline Products for Varicella Zoster (HHV-3) Infections 9
Varicella Zoster (HHV-3) Infections Therapeutics under Development by Companies 11
Varicella Zoster (HHV-3) Infections Therapeutics under Investigation by Universities/Institutes 13
Late Stage Products 14
Comparative Analysis 14
Mid Clinical Stage Products 15
Comparative Analysis 15
Early Clinical Stage Products 16
Comparative Analysis 16
Discovery and Pre-Clinical Stage Products 17
Comparative Analysis 17
Varicella Zoster (HHV-3) Infections Therapeutics – Products under Development by Companies 18
Varicella Zoster (HHV-3) Infections Therapeutics – Products under Investigation by Universities/Institutes 19
Companies Involved in Varicella Zoster (HHV-3) Infections Therapeutics Development 20
GlaxoSmithKline plc 20
Merck & Co., Inc. 21
Inhibitex, Inc. 22
Nutra Pharma Corporation 23
Summit Corporation plc 24
Clavis Pharma ASA 25
aRigen Pharmaceuticals, Inc. 26
Sinovac Biotech Ltd. 27
Epiphany Biosciences, Inc. 28
EMS S.A. 29
Varicella Zoster (HHV-3) Infections – Therapeutics Assessment 30
Assessment by Monotherapy Products 30
Assessment by Combination Products 31
Assessment by Route of Administration 32
Assessment by Molecule Type 34
Drug Profiles 36
FV-100 - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
RPI-78M - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
ARYS-01 - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
CP-4018 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
EPB-348 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Zoster - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Varicella-Zoster Vaccine - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
ZOSTAVAX - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
V212 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
Antiviral Program - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
Zostavax - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
Famciclovir - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
GSK208136 - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
Chickenpox Vaccine - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
Varilrix + Priorix-Tetra - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
Zostavax - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
Varicella Zoster (HHV-3) Infections Therapeutics – Drug Profile Updates 59
Varicella Zoster (HHV-3) Infections Therapeutics – Discontinued Products 62
Varicella Zoster (HHV-3) Infections Therapeutics - Dormant Products 63
Varicella Zoster (HHV-3) Infections – Product Development Milestones 65
Featured News & Press Releases 65
Jul 18, 2012: Agenus Annnounces Intiation Of Phase III Clinical Trial Of GSK's Herpes Zoster Vaccine Candidate In Immunocompromised Patients 65
Mar 15, 2012: CHMP Adopts Positive Opinion Recommending Variation To Terms Of Marketing Authorization For Proquad 66
Jan 28, 2011: Depomed Announces FDA Approval Of GRALISE Once-Daily Tablets For Treatment Of Post-Herpetic Neuralgia 66
Dec 13, 2010: Inhibitex Reports Promising Top-Line Results From Phase II Shingles Trial With FV-100 67
Oct 15, 2010: Inhibitex Completes Enrollment In Phase II Clinical Trial Of FV-100 In Shingles Patients 68
Aug 23, 2010: GSK Initiates Phase III Clinical Trials To Develop Herpes Zoster Vaccine For Prevention Of Shingles 69
Jul 22, 2010: Inhibitex Reports Independent Data Safety Monitoring Board Recommends Continuation Of Phase II Clinical Trial Of FV-100 69
Nov 18, 2009: Epiphany Announces Positive Results Of Its Drug Candidate Valomaciclovir From Its Phase 2b Trial In Shingles 69
Sep 09, 2008: Epiphany Biosciences Announces To Continue Phase 2 shingles Study After Interim Analysis 70
Nov 07, 2007: Epiphany Biosciences Reports Initiation And Enrollment In Valomaciclovir Study For Shingles 71
Appendix 72
Methodology 72
Coverage 72
Secondary Research 72
Primary Research 72
Expert Panel Validation 72
Contact Us 73
Disclaimer 73
List of Tables
Number of Products Under Development for Varicella Zoster (HHV-3) Infections, H2 2012 9
Products under Development for Varicella Zoster (HHV-3) Infections – Comparative Analysis, H2 2012 10
Number of Products under Development by Companies, H2 2012 12
Number of Products under Investigation by Universities/Institutes, H2 2012 13
Comparative Analysis by Late Stage Development, H2 2012 14
Comparative Analysis by Mid Clinical Stage Development, H2 2012 15
Comparative Analysis by Early Clinical Stage Development, H2 2012 16
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 17
Products under Development by Companies, H2 2012 18
Products under Investigation by Universities/Institutes, H2 2012 19
GlaxoSmithKline plc, H2 2012 20
Merck & Co., Inc., H2 2012 21
Inhibitex, Inc., H2 2012 22
Nutra Pharma Corporation, H2 2012 23
Summit Corporation plc, H2 2012 24
Clavis Pharma ASA, H2 2012 25
aRigen Pharmaceuticals, Inc., H2 2012 26
Sinovac Biotech Ltd., H2 2012 27
Epiphany Biosciences, Inc., H2 2012 28
EMS S.A., H2 2012 29
Assessment by Monotherapy Products, H2 2012 30
Assessment by Combination Products, H2 2012 31
Assessment by Stage and Route of Administration, H2 2012 33
Assessment by Stage and Molecule Type, H2 2012 35
Varicella Zoster (HHV-3) Infections Therapeutics – Drug Profile Updates 59
Varicella Zoster (HHV-3) Infections Therapeutics – Discontinued Products 62
Varicella Zoster (HHV-3) Infections Therapeutics – Dormant Products 63
Varicella Zoster (HHV-3) Infections Therapeutics – Dormant Products (Contd..1) 64
List of Figures
Number of Products under Development for Varicella Zoster (HHV-3) Infections, H2 2012 9
Products under Development for Varicella Zoster (HHV-3) Infections – Comparative Analysis, H2 2012 10
Products under Development by Companies, H2 2012 11
Products under Investigation by Universities/Institutes, H2 2012 13
Late Stage Products, H2 2012 14
Mid Clinical Stage Products, H2 2012 15
Early Clinical Stage Products, H2 2012 16
Discovery and Pre-Clinical Stage Products, H2 2012 17
Assessment by Monotherapy Products, H2 2012 30
Assessment by Combination Products, H2 2012 31
Assessment by Route of Administration, H2 2012 32
Assessment by Stage and Route of Administration, H2 2012 33
Assessment by Molecule Type, H2 2012 34
Assessment by Stage and Molecule Type, H2 2012 35
